A Generic Drug Face-Off Sends Mylan Soaring 19%
After the Food and Drug Administration surprisingly gave a green light to the company's Copaxone knockoff, shares in Mylan Inc. (NASDAQ: MYL) are surging 19.5% higher today at 11:30 a.m. EDT.
Teva Pharmaceutical (NYSE: TEVA) received bad news today when the FDA unexpectedly approved Mylan's long-lasting generic alternative to Copaxone 40 mg.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Teva Pharmaceutical Industries Ltd ADR Aktie
30,00 €
-2,96 %
Reines Buy-Sentiment für Teva Pharmaceutical Industries Ltd ADR, keine Sell-Einschätzungen in Sicht.
Das Community-Kursziel von 34 € für Teva Pharmaceutical Industries Ltd ADR deutet auf ein leicht positives Wachstumspotenzial gegenüber 30.0 € hin.
